Homes
Public Notices
News
Local news
Editor’s Pick
Pittsburgh
Local Government
My American Story
Roads, Travel and Traffic
Regional
U.S. and World
Business
Sports
HS Sports
College Sports
Penguins
Pirates
Steelers
Athlete of the Week
Wild Things
Pony Baseball
Outdoors
Columns
Opinion
Columns
Editorials
Letters to the Editor
Op Eds
Living
Neighbors
School News
Entertainment
Home and Garden
Food
Police Beat
Obituaries
Classifieds
Legal Notices
Jobs
Sponsored Content
e-Edition
close
Washington County
Greene County
Mon Valley
News
Local news
Police Beat
Pittsburgh
Local Government
Roads, Travel and Traffic
Helping The Helpers
My American Story
Regional
U.S. and World
Business News
Sports
High School Sports
College Sports
Penguins
Pirates
Steelers
Wild Things
Pro Sports
Outdoors
Sports Column
Obituaries
Opinion
Columns
Editorials
Letters to the Editor
Op-Ed
Living
Neighbors
Health and Wellness
Entertainment
Home and Garden
Classifieds
Jobs
Contact Us
Advertise With Us
Customer Service
Contact Information
Submission Forms
Statement of Values
Misc
Special Sections
Events
Sponsored Content
Newsletter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Articles published by Bioxodes
Final Phase 2a data reinforce the profile of BIOX-101, selected for a late-breaking oral presentation at the World Stroke Congress
Today 2:30 EDT
From
Bioxodes
Via
GlobeNewswire
Bioxodes presents positive final Phase 2a intracerebral hemorrhage results at ESOC affirming breakthrough potential of BIOX-101
May 06, 2026
From
Bioxodes
Via
GlobeNewswire
Bioxodes to present final Phase 2a trial results confirming breakthrough potential of BIOX-101 for intracerebral hemorrhage in poster at ESOC 2026
April 28, 2026
From
Bioxodes
Via
GlobeNewswire
Bioxodes expands Clinical Advisory Board, shares pivotal trial design for BIOX-101 in intracerebral hemorrhage
April 17, 2026
From
Bioxodes
Via
GlobeNewswire
Bioxodes raises €5.5 million Series A extension to continue preparations for pivotal trial of breakthrough stroke candidate
December 10, 2025
From
Bioxodes
Via
GlobeNewswire
Bioxodes presents BIOX-101 clinical data showing breakthrough potential for stroke in webcast with Prof Dr Robin Lemmens
November 14, 2025
From
Bioxodes
Via
GlobeNewswire
Bioxodes appoints industry veteran Philippe Monteyne as chairman as it accelerates late-stage development of breakthrough stroke candidate
October 07, 2025
From
Bioxodes
Via
GlobeNewswire
Bioxodes positive Phase 2a stroke data show breakthrough potential of innovative therapeutic candidate BIOX-101
September 11, 2025
From
Bioxodes
Via
GlobeNewswire
Bioxodes announces positive Phase 2a interim data for BIOX-101 in intracerebral hemorrhagic stroke patients
April 24, 2025
From
Bioxodes
Via
GlobeNewswire
Bioxodes obtains Orphan Drug Designation for hemorrhagic stroke therapeutic candidate in US and Europe
March 05, 2025
From
Bioxodes
Via
GlobeNewswire
Bioxodes secures new funds to reach early 2025 milestones and pursue Series B financing
February 12, 2025
From
Bioxodes
Via
GlobeNewswire
Bioxodes meets enrollment milestone in Phase 2a intracerebral hemorrhagic stroke trial
December 19, 2024
From
Bioxodes
Via
GlobeNewswire
Bioxodes reports positive DMC meeting for BIOX-101 Phase 2a trial in intracerebral hemorrhagic stroke
August 21, 2024
From
Bioxodes
Via
GlobeNewswire
Bioxodes meets first Phase 2a patient enrollment milestone with BIOX-101 in intracerebral hemorrhagic stroke
June 27, 2024
From
Bioxodes
Via
GlobeNewswire
Bioxodes receives European Patent Office intention to grant patent, offering lead asset broad protection in thromboinflammation
May 16, 2024
From
Bioxodes
Via
GlobeNewswire
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
Starting at
/week.
Subscribe Today